Alzheimers Disease Drug Development
Download Alzheimers Disease Drug Development full books in PDF, epub, and Kindle. Read online free Alzheimers Disease Drug Development ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Jeffrey Cummings |
| Publisher | : Cambridge University Press |
| Total Pages | : 575 |
| Release | : 2022-03-31 |
| Genre | : Business & Economics |
| ISBN | : 1108838669 |
Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
| Author | : Atta-ur Rahman |
| Publisher | : Elsevier |
| Total Pages | : 785 |
| Release | : 2015-06-27 |
| Genre | : Medical |
| ISBN | : 0128039604 |
Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. - Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development - Describes existing drugs for AD and current molecular understanding of the condition - Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
| Author | : Alan J. Sinclair |
| Publisher | : John Wiley & Sons |
| Total Pages | : 3453 |
| Release | : 2012-03-13 |
| Genre | : Medical |
| ISBN | : 1119954142 |
This new edition of the comprehensive and renowned textbook Principles and Practice of Geriatric Medicine offers a fully revised and updated review of geriatric medicine. It covers the full spectrum of the subject, features 41 new chapters, and provides up-to-date, evidence-based, and practical information about the varied medical problems of ageing citizens. The three editors, from UK, USA and France, have ensured that updated chapters provide a global perspective of geriatric medicine, as well as reflect the changes in treatment options and medical conditions which have emerged since publication of the 4th edition in 2006. The book includes expanded sections on acute stroke, dementia, cardiovascular disease, and respiratory diseases, and features a new section on end-of-life care. In the tradition of previous editions, this all-encompassing text continues to be a must-have text for all clinicians who deal with older people, particularly geriatric medical specialists, gerontologists, researchers, and general practitioners. This title is also available as a mobile App from MedHand Mobile Libraries. Buy it now from Google Play or the MedHand Store. Praise for the 4th edition: "...an excellent reference for learners at all clinical and preclinical levels and a useful contribution to the geriatric medical literature." —Journal of the American Medical Association, November 2006 5th edition selected for 2012 Edition of Doody's Core TitlesTM
| Author | : Menghis Bairu |
| Publisher | : Academic Press |
| Total Pages | : 428 |
| Release | : 2013-08-28 |
| Genre | : Medical |
| ISBN | : 0124115306 |
Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer's disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer's disease. - Written by leading experts with hands-on experience in designing and running global Alzheimer's disease and other neurodegenerative diseases clinical trials - A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area - Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer's disease global clinical trials in emerging markets and developing countries
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 107 |
| Release | : 2014-02-06 |
| Genre | : Medical |
| ISBN | : 0309292492 |
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
| Author | : Adeboye Adejare |
| Publisher | : Academic Press |
| Total Pages | : 0 |
| Release | : 2025-09-01 |
| Genre | : Medical |
| ISBN | : 0443300097 |
"Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease, 2nd Edition" examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success. The new edition of this book is updated with the most recent developments around the therapeutic strategies for drug discovery like amyloid hypothesis, tau, apo E, insulin, and others. It also includes a new chapter on drug delivery to the brain. The content covers diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. Pharmaceutical researchers will benefit from the updated coverage on therapeutic approaches to neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal disorder, Huntington's diseases and many more. Patients and advocacy groups can also benefit from the overview of current treatment options and the scientific progress in the field.• Covers Monoclonal Antibodies approaches• Provides a compilation of chemical considerations required in drug discovery for thetreatment of neurodegenerative disorders• Explores how in vitro and in vivo models translate to human physiology
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 101 |
| Release | : 2009-07-20 |
| Genre | : Medical |
| ISBN | : 0309142318 |
Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.
| Author | : Atta-ur-Rahman |
| Publisher | : Bentham Science Publishers |
| Total Pages | : 261 |
| Release | : 2020-06-02 |
| Genre | : Science |
| ISBN | : 9811410933 |
Frontiers in Clinical Drug Research - Dementia is a book series which presents comprehensive reviews about research on Dementia, - the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for dementia and related disorders. This volume includes the following reviews: - Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease - Cholesterol in Brain Health and Pathologies - Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia - Analytical Methods in Alzheimer’s Disease Drug Discovery - Targeting Alzheimer’s Disease through Nanomedicine - Current Challenges in Alzheimer’s Disease Research - Metals Linked to Alzheimer's Disease
| Author | : Tamas Bartfai |
| Publisher | : Academic Press |
| Total Pages | : 377 |
| Release | : 2013-05-18 |
| Genre | : Medical |
| ISBN | : 0124095194 |
The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. - Provides an in-depth, broad perspective on the crisis in drug industry - Exposes the disconnect between what society needs and what the drug companies are working on - Analyses and projects over 10 years into the future - Explains what it means for scientists and society - Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat
| Author | : Thimmaiah Govindaraju |
| Publisher | : Royal Society of Chemistry |
| Total Pages | : 531 |
| Release | : 2022-01-04 |
| Genre | : Medical |
| ISBN | : 1839162740 |
Alzheimer’s disease is an increasingly common form of dementia and despite rising interest in discovery of novel treatments and investigation into aetiology, there are no currently approved treatments that directly tackle the causes of the condition. Due to its multifactorial pathogenesis, current treatments are directed against symptoms and even precise diagnosis remains difficult as the majority of cases are diagnosed symptomatically and usually confirmed only by autopsy. Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities provides a comprehensive overview from aetiology and neurochemistry to diagnosis, evaluation and management of Alzheimer's disease, and latest therapeutic approaches. Intended to provide an introduction to all aspects of the disease and latest developments, this book is ideal for students, postgraduates and researchers in neurochemistry, neurological drug discovery and Alzheimer’s disease.
